KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other financing activities (2018 - 2024)

Alnylam Pharmaceuticals' Other financing activities history spans 7 years, with the latest figure at -$1.8 million for Q3 2024.

  • For Q3 2024, Other financing activities fell 121.24% year-over-year to -$1.8 million; the TTM value through Dec 2025 reached -$3.1 million, changed N/A, while the annual FY2025 figure was $2.4 million, N/A changed from the prior year.
  • Other financing activities reached -$1.8 million in Q3 2024 per ALNY's latest filing, down from -$1.3 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $22.3 million in Q3 2021 to a low of -$16.3 million in Q4 2023.
  • Average Other financing activities over 5 years is $3.5 million, with a median of $4.2 million recorded in 2020.
  • Peak YoY movement for Other financing activities: surged 432.14% in 2021, then crashed 317.77% in 2023.
  • A 5-year view of Other financing activities shows it stood at $4.2 million in 2020, then decreased by 16.67% to $3.5 million in 2021, then skyrocketed by 114.29% to $7.5 million in 2022, then plummeted by 317.77% to -$16.3 million in 2023, then skyrocketed by 89.16% to -$1.8 million in 2024.
  • Per Business Quant, the three most recent readings for ALNY's Other financing activities are -$1.8 million (Q3 2024), -$1.3 million (Q2 2024), and $3.1 million (Q1 2024).